Drew Moghanaki: EA5181 Study Findings Shared by Joe Y. Chang at TexasLung26

Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:

“Provocative finding from the EA5181 study shared by Joe Y Chang
at TexasLung26.

The in-field progression rate after the PACIFIC regimen is only in the single digits. A statistic that needs to be on the scale when surgical resection of N2 disease is considered.” Drew Moghanaki: EA5181 Study Findings Shared by Joe Y. Chang at TexasLung26